Montañez, Maria IMartin-Serrano, AngelaMayorga, CristobalinaBarrionuevo, EstherPerez, NataliaRomano, AntoninoMoreno, EstherAriza, AdrianaPerez-Inestrosa, EzequielTorres, Maria J2023-02-082023-02-082020-04-30Montañez MI, Martín-Serrano A, Mayorga C, Barrionuevo E, Pérez N, Romano A, et al. Reply. J Allergy Clin Immunol. 2020 Aug;146(2):460-461http://hdl.handle.net/10668/15491We appreciate Baldo’s1 interest regarding our article,2 and his observations about both the precise cefaclor antigenic determinant structures and the uncertainly regarding structures attached in the solid phase. Concerning ‘‘solid-phase poly-L-Lysine-cefaclor,’’ no mild conditions were used to preserve the integrity of the cefaclor molecule in its conjugate fragmentation, resulting in an undefined mix of structures on the solid phase. Specifically, poly-L-Lysine-solid phases were treated with a cefaclor solution (10 mg/mL) in aqueous buffer at pH 10.2 (0.05 MNa2CO3/NaHCO3).enCefaclorEpitopesHumansImmunoglobulin EEpitopesCefaclorPolylysineHydrogen-Ion Concentrationresearch article32362530Restricted AccessLisinaTamponesSolucionesConcentración de iones de hidrógenoEpítopos10.1016/j.jaci.2020.03.0231097-6825http://www.jacionline.org/article/S0091674920304309/pdf